Joshua Richter, MD, gives an overview of relapse/refractory multiple myeloma and the available treatment options.
Evaluating XPO1 Inhibitors in Multiple Myeloma and their Potential Role in Myelofibrosis
Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.
Joshua Richter, MD, reviews data from two clinical trials investigating selinexor combination therapies for the treatment of multiple myeloma.
Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.
Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.
Dr Joshua Richter explains which patients with multiple myeloma are most suitable for triplet combination therapies.
Srdan Verstovsek, MD, provides an overview of myelofibrosis and the clinical signs and symptoms to look for.
Dr Srdan Verstovsek, MD, details how the JAK-STAT pathway is utilized in the treatment of myelofibrosis.
Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.
Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
